Heparin-induced thrombocytopenia epidemiology and demographics: Difference between revisions
m (Protected "Heparin-induced thrombocytopenia epidemiology and demographics": Robot: Protecting all pages from category Drugs ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-msbeih@perfuse.org +msbeih@wikidoc.org, -psingh@perfuse.org +psingh13579@gmail.com, -agovi@perfuse.org +agovi@wikidoc.org, -rgudetti@perfuse.org +ravitheja.g@gmail.com, -lbiller@perfuse.org +lbiller@wikidoc.org,...) |
||
Line 1: | Line 1: | ||
{{Heparin-induced thrombocytopenia}} | {{Heparin-induced thrombocytopenia}} | ||
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto: | {{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com] | ||
==Overview== | ==Overview== | ||
[[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. It has been found to occur with increased frequencies in females, white population and patients over age of 60 years. An episode of [[Heparin-induced thrombocytopenia]] increases risks for other future thrombo-embolic events. | [[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. It has been found to occur with increased frequencies in females, white population and patients over age of 60 years. An episode of [[Heparin-induced thrombocytopenia]] increases risks for other future thrombo-embolic events. |
Revision as of 14:58, 2 November 2012
Heparin-induced thrombocytopenia |
Differentiating Heparin-induced thrombocytopenia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Heparin-induced thrombocytopenia epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia epidemiology and demographics |
FDA on Heparin-induced thrombocytopenia epidemiology and demographics |
CDC on Heparin-induced thrombocytopenia epidemiology and demographics |
Heparin-induced thrombocytopenia epidemiology and demographics in the news |
Blogs on Heparin-induced thrombocytopenia epidemiology and demographics |
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
Risk calculators and risk factors for Heparin-induced thrombocytopenia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. It has been found to occur with increased frequencies in females, white population and patients over age of 60 years. An episode of Heparin-induced thrombocytopenia increases risks for other future thrombo-embolic events.
Epidemiology and demographics
Mortality
- Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. The affected individuals have an increased risks of having another thromboembolic event (20-50% increased risks)
- Mortality rate can be as high as 20%
- 1 in 10 patients suffer from other morbidities (amputations or other arterial venous or both thrombo-embolic events)
United States of America
- Incidence varies from 1-5%.
Race
Some studies have shown that the incidences of heparin-induced thrombocytopenia (HIT) are commoner among white patients compared to non-white patients.
Sex
Female have increased risks compared to male for heparin-induced thrombocytopenia
Age
Risks for development of HIT Increases with age (>60years)